| Literature DB >> 28685073 |
Hiroaki Soyama1, Masashi Takano2, Morikazu Miyamoto1, Tomoyuki Yoshikawa2, Tadashi Aoyama1, Tomoko Goto1, Junko Hirata1, Ayako Suzuki1, Hidenori Sasa1, Kenichi Furuya1.
Abstract
The aim of the present study was to identify clinicopathological factors in long-term survivors following ovarian cancer recurrence. The patients who achieved longer survival after recurrence (n=18) and those who succumbed to the disease earlier (n=47) were identified and analyzed. There were no significant differences in age, performance status, stage distribution or histology between the two groups. Additionally, no significant difference was observed in progression-free survival after primary therapy. Multivariate analyses revealed that the predictive factors for long-term survival were i) secondary debulking surgery (OR=13.3; 95% CI: 1.39-226.7), ii) favourable response rate of second-line chemotherapy (OR=46.5; 95% CI: 1.84-313-4), and iii) ≥3 regimens after first recurrence (OR=9.01; 95% CI: 1.28-117.7). This study revealed that prolonged post-progression survival was associated with post-recurrence treatment. Therefore, appropriate selection of secondary debulking surgery and better chemotherapeutic response may lead to prolonged post-progression survival in recurrent ovarian cancer patients.Entities:
Keywords: chemotherapy; ovarian cancer; overall survival; post-progression survival; recurrence; secondary debulking surgery
Year: 2017 PMID: 28685073 PMCID: PMC5492634 DOI: 10.3892/mco.2017.1266
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450